Drug Trial Radar · NCT00327470
An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD
Last checked: Nov 20, 2026Latest source record: Apr 4, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
288
Actual
Start
Jul 2006
Primary completion
Aug 2009
Study completion Aug 2009
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 18, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the benefits of treating subjects with neovascular age-related macular degeneration (AMD) at an earlier stage of choroidal neovascularization (CNV) as compared to those with established CNV. Additionally, the study would like to determine the efficacy of Macugen in preserving visual function in those subjects having CNV secondary to neovascular AMD.
Conditions
- Age Related Macular Degeneration (AMD)
- Macular Degeneration
- Choroidal Neovascularization (CNV)
Interventions
Pegaptanib Sodium 0.3 mgDrug
Pegaptanib Sodium dosed every 6 weeks in affected eye.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline Through Week 54 in Distance Visual Acuity (VA) in Subjects With Early and Established CNV LesionsTime frame: Baseline through Week 54
Locations
58 sites in 15 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Graz, Austria
Pfizer Investigational Site
Innsbruck, Austria
Pfizer Investigational Site
Vienna, Austria
Pfizer Investigational Site
Vienna, Austria
Pfizer Investigational Site
Brussels, Belgium
Pfizer Investigational Site
Brussels, Belgium
Pfizer Investigational Site
Liège, Belgium
Pfizer Investigational Site
Victoria, British Columbia, Canada
Pfizer Investigational Site
Victoria, British Columbia, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
London, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Olomouc, Czechia
Pfizer Investigational Site
Prague, Czechia
Pfizer Investigational Site
Prague, Czechia
Pfizer Investigational Site
Prague, Czechia
Pfizer Investigational Site
Glostrup Municipality, Denmark
Pfizer Investigational Site
Kuopio, Finlad, Finland
Pfizer Investigational Site
Marseille, France
Pfizer Investigational Site
Nancy, France
Pfizer Investigational Site
Nantes, France
Pfizer Investigational Site
Paris, France
Pfizer Investigational Site
Paris, France
Pfizer Investigational Site
Saint-Etienne, France
Pfizer Investigational Site
Tours, France
Pfizer Investigational Site
Dortmund, Germany
Pfizer Investigational Site
Freiburg im Breisgau, Germany
Pfizer Investigational Site
Halle, Germany
Pfizer Investigational Site
Münster, Germany
Pfizer Investigational Site
Athens, Greece
Pfizer Investigational Site
Athens, Greece
Pfizer Investigational Site
Ancona, Italy
Pfizer Investigational Site
Bari, Italy
Pfizer Investigational Site
Florence, Italy
Pfizer Investigational Site
Milan, Italy
Pfizer Investigational Site
Milan, Italy
Pfizer Investigational Site
Gdansk, Poland
Pfizer Investigational Site
Katowice, Poland
Pfizer Investigational Site
Poznan, Poland
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.